Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares GlobeNewswire October 27, 2025 MILAN and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) — Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that it has entered into a securities purchase agreement with institutional investors to purchase 4,285,715 American Depositary Shares […]

At Phase 2 of the 138th Canton Fair, the Gardening Products and Weaving, Rattan & Iron Products sections are attracting strong interest for their focus on practical aesthetics, merging everyday functionality with artistry and sustainable design. Exhibitors are demonstrating how craftsmanship and green innovation can elevate the beauty and usability of modern living spaces. A

— The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group — DREAMS-3 is the world's first Phase 3 clinical trial of a GCG/GLP-1 dual receptor agonist to conduct a head-to-head comparison with semaglutide in diabetes

Augmentus, the Singapore-based pioneer in AI-robotics and adaptive automation, today announced a strategic investment from Applied Ventures, LLC, the venture capital arm of Applied Materials, Inc. This investment marks a significant milestone in Augmentus' mission to enable intelligent, autonomous robotics for high-mix, high-variability manufacturing across the globe. https://mma.prnewswire.com/media/2804324/Figure_1.jpg At the heart of Augmentus' innovation is

Augmentus, the Singapore-based pioneer in AI-robotics and adaptive automation, today announced a strategic investment from Applied Ventures, LLC, the venture capital arm of Applied Materials, Inc. This investment marks a significant milestone in Augmentus' mission to enable intelligent, autonomous robotics for high-mix, high-variability manufacturing across the globe. https://mma.prnewswire.com/media/2803651/Figure_1.jpg At the heart of Augmentus' innovation is

— The company presented the 'AIN Family' which consists of NAND solution products optimized for performance(P), bandwidth(B), and density(D) respectively for AI — SK hynix held 'HBF Night' to expand the 'AIN B'(HBF product) ecosystem with a number of global big tech officials in attendance — Company will collaborate closely with customers and partners to

(NASDAQ:FFAI), The UAE launch of the FX Super One will take place on October 28 at the Armani Hotel, Burj Khalifa, Dubai. LOS ANGELES, Oct. 26, 2025 (GLOBE NEWSWIRE) — Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global shared intelligent electric mobility ecosystem company, today shared a

(NASDAQ:BIIB), TOKYO and CAMBRIDGE, Mass., Oct. 26, 2025 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for humanized anti-soluble aggregated amyloid-beta (AB) monoclonal

Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FF Finance Company has Been Established and Completed its Financial License Application; BlackRock has Further Increased its Holdings in FFAI; The First Superstar Owner of the FX Super One is About to be Revealed GlobeNewswire October 26, 2025 The UAE launch of the FX

Health Canada Grants Authorization for “LEQEMBI(R)” (lecanemab) for the Treatment of Early Alzheimer's Disease In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*) non-carriers or heterozygotes and who have